Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring.

作者: Isabel Spriet , Wouter Meersseman , Liesbet Henckaerts , Willy Peetermans

DOI: 10.2143/ACB.66.3.2062555

关键词:

摘要: Posaconazole is a recently developed broad-spectrum triazole antifungal with potential for long-term prophylaxis or therapy of invasive fungal infections. This case illustrates the additive value therapeutic drug monitoring to guide clinical decision-making in high risk patients.

参考文章(6)
Brahm H. Segal, Thomas L. Leto, John I. Gallin, Harry L. Malech, Steven M. Holland, Genetic, biochemical, and clinical features of chronic granulomatous disease Medicine. ,vol. 79, pp. 170- 200 ,(2000) , 10.1097/00005792-200005000-00004
David Andes, Andres Pascual, Oscar Marchetti, Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications Antimicrobial Agents and Chemotherapy. ,vol. 53, pp. 24- 34 ,(2009) , 10.1128/AAC.00705-08
Stéphanie Chhun, Elisabeth Rey, Agnes Tran, Olivier Lortholary, Gérard Pons, Vincent Jullien, Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. Journal of Chromatography B. ,vol. 852, pp. 223- 228 ,(2007) , 10.1016/J.JCHROMB.2007.01.021
Farkad Ezzet, David Wexler, Rachel Courtney, Gopal Krishna, Josephine Lim, Mark Laughlin, Oral Bioavailability of Posaconazole in Fasted Healthy Subjects Clinical Pharmacokinetics. ,vol. 44, pp. 211- 220 ,(2005) , 10.2165/00003088-200544020-00006
Thomas J. Walsh, Issam Raad, Thomas F. Patterson, Pranatharthi Chandrasekar, Gerald R. Donowitz, Richard Graybill, Reginald E. Greene, Ray Hachem, Susan Hadley, Raoul Herbrecht, Amelia Langston, Arnold Louie, Patricia Ribaud, Brahm H. Segal, David A. Stevens, Jo‐Anne H. van Burik, Charles S. White, Gavin Corcoran, Jagadish Gogate, Gopal Krishna, Lisa Pedicone, Catherine Hardalo, John R. Perfect, Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial Clinical Infectious Diseases. ,vol. 44, pp. 2- 12 ,(2007) , 10.1086/508774